SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Yul Brynner — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientYul Brynner
Date of birth1920-07-11
IdentifiersMRN HR-ML020-SYN-TD; SSN (made up) 000-20-4572
Document date1983-09-15
AuthorSimon Achterberg, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Diagnosis and staging review. [S]

History of Present Illness

Mr. Brynner returns two weeks after his first visit. His PET-CT and brain MRI were done eleven days ago, and the endobronchial ultrasound biopsy six days ago. He saw the thoracic oncologist this morning and was told he has adenocarcinoma of the lung that has spread to three bones. His voice is still weak and breathy, and he has not sung since the tour paused. He has a little dry cough in the mornings, no blood in his sputum, and no breathlessness on the level. He has no bone, back, rib, or hip pain, no headache, and no weakness or numbness. His weight is steady. He is sleeping less well with worry, but he says he wants every fact and wants to get back on stage. He has not smoked for 12 years. [S]

ElementDetail
Results since last visitPET-CT and brain MRI; endobronchial ultrasound biopsy: adenocarcinoma, PD-L1 70 percent; plasma testing without an actionable alteration; tissue sequencing pending
VoiceWeak and breathy; not singing
RespiratoryMorning dry cough; no hemoptysis; no breathlessness on the level
Bone and neurological symptomsNone
CopingWorried and sleeping less; distress thermometer 6 of 10

Review of Systems

SystemResultFinding
RespiratoryPositiveMorning dry cough; breathless on two flights of stairs; no hemoptysis
MusculoskeletalNegativeNo bone, back, rib, or hip pain
NeurologicalNegativeNo headache, weakness, numbness, or unsteadiness
PsychiatricPositiveWorried; sleeping about five hours; no thoughts of self-harm

4 systems reviewed. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1983-09-15Body height178cmS
1983-09-15Body weight72kgS
1983-09-15Body mass index (BMI) [Ratio]22.7kg/m2S
1983-09-15Systolic blood pressure128mm[Hg]S
1983-09-15Diastolic blood pressure78mm[Hg]S
1983-09-15Heart rate80/minS
1983-09-15Respiratory rate16/minS
1983-09-15Body temperature36.7CelS
1983-09-15Oxygen saturation in Arterial blood by Pulse oximetry96%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1983-09-15Total score [Edmonton Symptom Assessment System]18{score}S

Physical Exam

Vital signs recorded on 1983-09-15; see the Vital Signs section. [S]

SystemFinding
GeneralUpright and composed; weight 72.0 kg
VoiceBreathy, low-volume voice; short phonation time
LungsSlightly reduced breath sounds at the left apex; no wheeze or crackles
Lymph nodesNo supraclavicular or cervical nodes
Spine and pelvisNo tenderness over T10, the ribs, or the right iliac crest
NeurologicalNormal strength, sensation, and gait

Problems

ProblemClinical statusVerificationCodeProvenance
Adenocarcinoma of the left upper lobe of the lung, stage IVB (cT4 N2 M1c, AJCC 8th edition), unresectable: the primary invades the mediastinum at the aortopulmonary window; bone metastases; PD-L1 tumor proportion score 70 percent (22C3); ECOG performance status 1; comprehensive genomic profiling results in the notesactiveconfirmed C34.12S — Synthetic modern histology, stage, and biomarkers linked to his documented inoperable lung cancer of September 1983.
Bone metastases at T10, the right ilium, and the left sixth rib on PET-CT, without pain, fracture, or cord compressionactiveconfirmed C79.51S — Synthetic metastatic sites chosen so that first-line systemic therapy is the standard of care; no source describes the spread of his cancer.
Left vocal fold paralysis with a breathy, weak voice, most likely from left recurrent laryngeal nerve involvement by disease in the aortopulmonary windowactiveconfirmed J38.01S — Synthetic laryngoscopy finding anchored to the published account that a vocal-cord problem led to his diagnosis; the lay 'lump on his vocal cords' is not modeled as a laryngeal tumor.
Left upper lobe mass invading the mediastinum, with enlarged mediastinal lymph nodes, on CT at presentation; suspicious for lung cancer pending tissue diagnosisactiveconfirmed R91.8S — Synthetic presenting imaging finding, recorded before the tissue diagnosis.
Former smoker: about 3 packs a day from age 12 until he quit 12 years ago, roughly 115 pack-years; no tobacco sinceactiveconfirmed Z87.891S — Synthetic modern entry linked to the documented heavy smoking and quitting; the pack-year figure is a synthetic midpoint of conflicting published amounts.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPD-L1 immunohistochemistry (tumor proportion score)At diagnosis; repeat at progressionCompleted today22C3 assay on the endobronchial ultrasound sample: tumor proportion score 70 percent
LaboratoryBroad molecular profiling (tissue and plasma)At diagnosis of advanced nonsquamous NSCLC: EGFR, ALK, ROS1, BRAF, KRAS (including G12C), MET exon 14, RET, NTRK, HER2, NRG1, and PD-L1; repeat at progressionOrderedPlasma cell-free DNA: no actionable alteration. Tissue next-generation sequencing pending; therapy waits for it
ImagingStaging PET-CT and brain MRIAt diagnosis of suspected advanced diseaseCompleted todayReviewed today: cT4 N2 M1c (bone), no brain metastases
LaboratoryImmune-related adverse event laboratory panelBefore each immunotherapy infusion: TSH, liver tests, glucose; cortisol at baseline and as indicatedDueBaseline panel before the first infusion
ImagingResponse assessment imagingEvery 6 to 12 weeks on active systemic therapyNot indicatedNo systemic therapy started yet
ExaminationDyspnea and cough assessmentEvery visitCompleted todayMorning dry cough; breathless on two flights of stairs; no hemoptysis
Self-managementSmoking status and cessation supportEvery visitCompleted todayFormer smoker; no tobacco for 12 years
SurveyDistress and symptom screening (NCCN Distress Thermometer, ESAS)Every visit; at minimum at key transitionsCompleted todayDistress thermometer 6 of 10 (worry, work, voice); ESAS total 18
SurveyCancer-related fatigue screeningEvery visitCompleted todayTires by evening; ESAS tiredness 4 of 10
SurveyDepression and anxiety screeningAt least yearly; more often during active treatmentUp to datePHQ-9 5 two weeks ago; rescreen during treatment
ExaminationWeight and dietary reviewEach follow-upCompleted today72.0 kg, stable; eating normally
Medication safetyDental evaluation before a bone-modifying agentBaseline, then periodically on zoledronic acid or denosumabDueDental examination booked for Friday
Medication safetyChemotherapy-induced peripheral neuropathyEvery visit during and after platinum or taxaneNot indicatedNo platinum or taxane planned
ReferralThoracic oncology consultationAt diagnosisCompleted todaySeen today; stage IVB confirmed; pembrolizumab planned if tissue sequencing shows no actionable alteration
ReferralEarly integrated palliative careWithin eight weeks of diagnosis of advanced cancerReferredFirst visit in two weeks
Self-managementAdvance care planning and goals of careAt diagnosis and at changes in healthCompleted todayFirst conversation today: he wants full information and full treatment, and to return to the stage
Self-managementVoice and work supportAs neededReferredInjection medialization and voice therapy arranged
Medication safetyImmunizations per ACIPYearly reviewDueInfluenza, pneumococcal, zoster, COVID-19, and RSV to be reviewed at the preventive visit
ExaminationPulmonary rehabilitationBefore and after lung resection, or for symptomatic dyspnea or deconditioningNot indicatedNo resection; not deconditioned

Goal progress:

Guideline basis: CMID: Clinical Monitoring Intelligence Database, lung cancer monograph (2026); NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (2021); Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017); NCCN Clinical Practice Guidelines in Oncology: Distress Management (2026)

Follow-up: Dental examination on Friday. Visit next week for the tissue sequencing result and the treatment start. Palliative care in two weeks. Voice injection in three weeks. Next scheduled visit 1983-09-22: biomarker results and start of first-line pembrolizumab. [S]